Quick Takeaways
- Robert E. Gagnon has 5 issuer positions tracked on this page.
- Estimated disclosed ownership value: $5,080,163.
- Recent insider filing activity is available below.
Insider Trading & Ownership of Robert E. Gagnon
- Location
- Needham, MA
- Summary
- The estimated net worth of Robert E. Gagnon is at least $5,080,163 dollars as of 27 Apr 2026. Robert E. Gagnon is the Chief Financial Officer of Opus Genetics, Inc. and owns shares of Opus Genetics, Inc. (IRD) stock worth about $3.07M. Robert E. Gagnon is the Director of PURPLE BIOTECH LTD. and owns shares of PURPLE BIOTECH LTD. (PPBT) stock worth about $1.53M. Robert E. Gagnon is the Director of Verastem, Inc. and owns shares of Verastem, Inc. (VSTM) stock worth about $380.9K. Robert E. Gagnon is the Director of Bone Biologics Corp and owns shares of Bone Biologics Corp (BBLG) stock worth about $49.1K. Robert E. Gagnon is the Director of HARVARD BIOSCIENCE INC and owns shares of HARVARD BIOSCIENCE INC (HBIO) stock worth about $48.8K.
- Signature
- /s/ Amy Rabourn, by Power of Attorney
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Robert E. Gagnon and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
What Changed
- Largest disclosed position: Opus Genetics, Inc. ($3,070,102).
- Past-year value change for that position: -$40,658.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Robert E. Gagnon
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| IRD | Opus Genetics, Inc. | Chief Financial Officer | $3,070,102 | -$40,658 | -1.3% | 23 Apr 2026 |
| PPBT | PURPLE BIOTECH LTD. | Director | $1,531,250 | 18 Mar 2026 | ||
| VSTM | Verastem, Inc. | Director | $380,936 | -$6,998 | -1.8% | 16 Dec 2025 |
| BBLG, BBLGW | Bone Biologics Corp | Director | $49,057 | 04 Jun 2025 | ||
| HBIO | HARVARD BIOSCIENCE INC | Director | $48,818 | 16 Jul 2025 |
Insider Transactions Reported by Robert E. Gagnon:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.